US OptionsDetailed Quotes
CASI250117P7500
- 0.00
- 0.000.00%
15min DelayClose Dec 31 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover262.40%IV-165.02%PremiumJan 17, 2025Expiry Date4.67Intrinsic Value100Multiplier16DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9327Delta0.0895Gamma0.60Leverage Ratio-0.0055Theta-0.0019Rho-0.56Eff Leverage0.0008Vega
CASI Pharmaceuticals Stock Discussion
📊⚡️📊
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia
CASI Pharmaceuticals (NASDAQ:CASI) has received Clinical Trial Application (CTA) approval from China's NMPA to conduct a phase 1/2 study of CID-103 in adult patients with chronic Immune Thrombocytopenia (ITP). The China study is part of a global study previously approved by the US FDA in May 2024. CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody that...
$MicroCloud Hologram (HOLO.US)$ $Loop Media (LPTV.US)$ $CASI Pharmaceuticals (CASI.US)$ $Petco Health and Wellness (WOOF.US)$ $Clearmind Medicine (CMND.US)$ $Innovative Eyewear (LUCY.US)$
📊⚡️📊
No comment yet